Inflammatory infiltrate populations in hIL-17E transgenic tissues
| . | CD19+ . | CD4+ . | CD3+ . | CD5+CD19+ . | CD34+CD19+ . | CCR3+ . |
|---|---|---|---|---|---|---|
| Blood (× 106cells)* | ||||||
| Nontransgenic (NTg) | 1.49 ± 0.39 | 0.78 ± 0.26 | 1.85 ± 0.55 | ND | ND | ND2-153 |
| Transgenic (Tg) | 6.17 ± 4.81 | 2.27 ± 0.78 | 3.43 ± 1.41 | ND | ND | ND2-153 |
| Spleen (× 107cells)* | ||||||
| Nontransgenic | 3.88 ± 0.94 | 1.49 ± 0.12 | 2.71 ± 0.55 | ND | ND | 0.34 ± 0.12 |
| Transgenic | 9.80 ± 0.33 | 2.72 ± 0.81 | 4.03 ± 1.40 | ND | ND | 6.78 ± 5.82 |
| Lymph node (× 106cells)†,2-155 | ||||||
| Nontransgenic | 4.20 ± 0.21 | 4.94 ± 0.14 | 8.0 ± 2.7 | 0.31 ± 0.112-155 | 0.10 ± 0.032-155 | 0.09 ± 0.062-155 |
| Transgenic | 64.12 ± 5.21 | 28.43 ± 27.37 | 43.0 ± 35.4 | 6.66 ± 0.842-155 | 4.78 ± 1.932-155 | 28.67 ± 18.482-155 |
| Bone marrow (× 106cells)‡ | ||||||
| Nontransgenic | 3.02 ± 1.61 | ND | ND | 0.08 ± 0.04 | 0.13 ± 0.06 | 0.08 ± 0.03 |
| Transgenic | 1.90 ± 1.17 | ND | ND | 0.04 ± 0.03 | 0.05 ± 0.03 | 0.74 ± 0.40 |
| . | CD19+ . | CD4+ . | CD3+ . | CD5+CD19+ . | CD34+CD19+ . | CCR3+ . |
|---|---|---|---|---|---|---|
| Blood (× 106cells)* | ||||||
| Nontransgenic (NTg) | 1.49 ± 0.39 | 0.78 ± 0.26 | 1.85 ± 0.55 | ND | ND | ND2-153 |
| Transgenic (Tg) | 6.17 ± 4.81 | 2.27 ± 0.78 | 3.43 ± 1.41 | ND | ND | ND2-153 |
| Spleen (× 107cells)* | ||||||
| Nontransgenic | 3.88 ± 0.94 | 1.49 ± 0.12 | 2.71 ± 0.55 | ND | ND | 0.34 ± 0.12 |
| Transgenic | 9.80 ± 0.33 | 2.72 ± 0.81 | 4.03 ± 1.40 | ND | ND | 6.78 ± 5.82 |
| Lymph node (× 106cells)†,2-155 | ||||||
| Nontransgenic | 4.20 ± 0.21 | 4.94 ± 0.14 | 8.0 ± 2.7 | 0.31 ± 0.112-155 | 0.10 ± 0.032-155 | 0.09 ± 0.062-155 |
| Transgenic | 64.12 ± 5.21 | 28.43 ± 27.37 | 43.0 ± 35.4 | 6.66 ± 0.842-155 | 4.78 ± 1.932-155 | 28.67 ± 18.482-155 |
| Bone marrow (× 106cells)‡ | ||||||
| Nontransgenic | 3.02 ± 1.61 | ND | ND | 0.08 ± 0.04 | 0.13 ± 0.06 | 0.08 ± 0.03 |
| Transgenic | 1.90 ± 1.17 | ND | ND | 0.04 ± 0.03 | 0.05 ± 0.03 | 0.74 ± 0.40 |
Populations are representative of transgenic founders or F1 progeny and were determined by FACS analysis using conjugated antibodies against indicated markers. Values reported as mean ± SEM (absolute number of cells); ND indicates not determined.
NTg, n = 5; Tg, n = 6.
NTg, n = 2; Tg, n = 4.
NTg, n = 5; Tg, n = 10.
Indicates eosinophil values reported in Table 1 by CBC analysis.
CD5+CD19+ and CD34+CD19+, NTg, n = 3; Tg, n = 3. CCR3+, NTg, n = 4; Tg, n = 6; all values are × 106cells.